MoonLake Immunotherapeutics MLTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $54.52M-2.7% | $56.01M-7.6% | $60.64M+21.9% | $49.76M+36.5% | $36.46M-9.7% | ||
| $70.02M+7.4% | $65.22M-8.7% | $71.43M+17.7% | $60.7M+27.8% | $47.49M-4.2% | ||
| $622K+151% | $248K+116% | $115K+21.1% | $95K-37.9% | $153K+273% | ||
| -$69.71M-11.7% | -$62.43M+10.5% | -$69.73M-26.3% | -$55.22M-38.2% | -$39.94M+12.4% | ||
| -$69.18M-7.3% | -$64.47M+8.8% | -$70.69M-17.9% | -$59.96M-27.3% | -$47.11M+4.3% | ||
| -$70.02M-7.4% | -$65.22M+8.7% | -$71.43M-17.7% | -$60.7M-27.8% | -$47.49M+4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MoonLake Immunotherapeutics profitable?
- MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
- What is MoonLake Immunotherapeutics's earnings per share?
- MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.